Effect of Ensifentrine Treatment on CAT Score
Clinical trial NCT06460493 · COMPLETED
Trial details
- NCT number
- NCT06460493
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-11
- Primary completion
- 2024-11-26
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.